News | January 03, 2024
Glenmark to launch biosimilar of anti-diabetic drug Liraglutide in India
Liraglutide belongs to the class of glucagon like peptide 1 receptor agonist (GLP?1 RA) drugs
Liraglutide belongs to the class of glucagon like peptide 1 receptor agonist (GLP?1 RA) drugs
10+ emerging markets, Japan & ANZ transition in final phase
The full transition of Viatris' biosimilars operations to Biocon Biologics in Europe represents another significant milestone
Yesafili, received marketing authorization approval from the European Commission for the European Union
The company had submitted a comprehensive Corrective and Preventive Action (CAPA) plan in September 2022
The centralized marketing authorization granted by the EC is valid in all EU Member States as well as in the European Economic Area (EEA) countries Iceland, Liechtenstein and Norway
Biocon Biologics recently acquired the global biosimilars business of its long-term partner Viatris
Planned investment of approximately USD 90 million to build a state-of-the-art Sandoz Biosimilar Technical Development Center in Ljubljana, Slovenia by 2026
The launch of HULIO in the United States is an important milestone for Biocon Biologics
This request for withdrawal of the two dossiers was made after necessary consultations and receiving guidance from EMA
Subscribe To Our Newsletter & Stay Updated
